2025-12-04 - Analysis Report
Okay, let's break down the analysis of Johnson & Johnson (JNJ) based on the provided data.

**1. Return Rate Comparison:**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 58.81%
*   **S&P 500 (VOO) Cumulative Return:** 100.36%
*   **Divergence:** -42.0 (Relative Divergence: 28.6)

**Analysis:**

*   JNJ has significantly underperformed the S&P 500 over the period examined.  The S&P 500 has produced nearly double the return of JNJ.
*   The divergence of -42.0 indicates a substantial difference in performance. The relative divergence of 28.6 suggests that the current divergence is closer to the minimum divergence observed in the past.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.6 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.9 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 351.5 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 379.2 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 412.2 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 425.6 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 377.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 348.4 |
| 2023-2025  | 30.0% | 79.6% | -35.0% | 0.1 | 496.5 |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate fluctuates significantly, with some periods showing strong growth and others experiencing losses.
*   **MDD:** The Maximum Drawdown is consistently high, indicating considerable risk.
*   **Alpha:**  The Alpha is mostly negative, suggesting that JNJ has generally underperformed relative to its expected return based on its beta.  The later years show significantly negative Alpha.
*   **Beta:** The Beta is consistently below 1, indicating that JNJ is less volatile than the market (S&P 500).

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 206.065
*   **Last Market Data:** Price = 205.99, Previous Close = 205.42, Change = 0.28
*   **5-day SMA:** 206.305
*   **20-day SMA:** 198.001
*   **60-day SMA:** 189.2983

**Analysis:**

*   The price is currently above all moving averages. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This suggests a recent upward trend.
*   The recent market data shows a small price increase, indicating a slight positive movement.

**3. RSI, PPO Indicators and Divergence:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 82.65 (Overbought)
*   **PPO:** 0.2324
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (12 shares - Very Safe - MRI:0.90) (Cash Ratio: 0% on 2025-12-02)
*   **Recent (20 days) relative divergence change:** -6.4 (-): 단기하락 (Short-term decline)
*   **Expected Return (%):** -56.9

**Analysis:**

*   **MRI:** The high MRI score suggests that market conditions are currently favorable for investment, but it's important to remember that the MRI is a broad market indicator and may not be specific to JNJ.
*   **RSI:** The RSI is in overbought territory, which could suggest a potential pullback in the near term.
*   **PPO:** The PPO (Percentage Price Oscillator) is a momentum indicator; the positive value suggests upward momentum.
*   **Hybrid Signal:** This suggests a strong buy signal based on the given parameters.
*   **Divergence Change:** The recent decline in relative divergence aligns with the underperformance versus the S&P 500.
*   **Expected Return:** The negative expected return is concerning and contradicts the 'Very Safe' hybrid signal. This is a critical point to investigate.  It implies that, based on the model used to calculate this, the stock is significantly overvalued.

**4. Recent News & Significant Events:**

*   **Positive Developments:**  New EU drug approval, oncology deal, analyst discussing whether to buy, sell or hold the stock (suggesting increased attention). Quantbot Technologies purchased shares.
*   **Promotional Activities:**  Partnership with Naomi Watts to promote eye exams.
*   **Valuation Focus:**  Articles exploring the stock's valuation following recent trading moves.
*   **Insider Activity:** Director purchased shares.

**Analysis:**

*   The news is a mixed bag.  The drug approval and oncology deal are positive.  The insider purchase is generally viewed positively as well.  However, the articles discussing valuation suggest the price is under scrutiny.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** Average 202.54 (Current Price is ~206, so slightly overvalued based on average target)

**Analysis:**

*   Analysts generally have a positive outlook on JNJ, with a consensus rating of "Buy." However, the average target price is slightly below the current price.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|----------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

**Analysis:**

*   The data is inconsistent, showing the same date twice. Assuming the second `2025-10-22` should be `2024-10-23`:  Revenue shows a general upward trend in the past few quarters.
*   EPS has fluctuated significantly, but it's important to compare these values to previous years and analyst expectations to assess performance accurately.

**6. Financial Information**

Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

**Analysis:**

*   **Revenue:** Revenue has been steadily increasing, indicating strong sales performance.
*   **Profit Margin:** The profit margin is consistently high, demonstrating the company's ability to control costs.
*   **Equity:** Equity has been increasing, suggesting that the company is growing its asset base.
*   **ROE:** Return on Equity (ROE) has fluctuated, with a significant spike in March 2025. Overall, the ROE is generally positive, showing the company is generating profits from its shareholders' investments.

**7. Comprehensive Analysis:**

JNJ is a large, established company with a diversified business and generally positive analyst sentiment.  However, there are some conflicting signals:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 over the long term.
*   **Recent Momentum:**  Recent price action is positive, with the price above moving averages.
*   **Overbought RSI:** The overbought RSI suggests a possible pullback.
*   **Conflicting Signals:** The "Very Safe" hybrid signal clashes with the extremely negative expected return. This needs further investigation.
*   **Valuation Concerns:** Some news articles focus on valuation, and the average analyst target price is slightly below the current price.
*   **Positive Developments:** The company has secured new drug approvals and oncology deals, and there has been some insider buying.
*   **Strong Fundamentals:** Revenue and profit margins are consistently high.

**Conclusion:**

While JNJ appears to have strong fundamentals and recent positive momentum, the long-term underperformance, the potentially overbought RSI, and the extremely negative expected return raise concerns. It is crucial to understand the model that calculates the expected return to determine whether to buy it.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.